Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 7/20 | 1.00 |
| ▸ | BRD2 | P25440 | 4/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 3/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 2/20 | 1.00 |
| ▸ | DNER | Q8NFT8 | 2/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | BRD1 | O95696 | 1/20 | 1.00 |
| ▸ | CCL2 | P13500 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 1/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881473 | 1.00 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881227 | 1.00 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21320191 | 0.93 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL15984904 | 0.93 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL29424160 | 0.92 | BRD4 (0.85) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL25727485 | 0.92 | BRD4 (0.85) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL30372667 | 0.92 | BRD4 (0.86) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21303807 | 0.92 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23317871 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21349526 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540143-B2 | Methods and compositions for targeted protein degradation | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4658317-A1 | PROGRAMMABLE DNA PROTEOLYSIS TARGET CHIMERAS AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250327028-A1 | ENGINEERED PLATELETS AS TARGETED PROTEIN DEGRADERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4629984-A1 | DEVELOPMENT OF POTENT DUAL HDAC/BRD4 INHIBITORS | BioVentures, LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4622947-A1 | ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS | Dana-Farber Cancer Institute, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4608876-A2 | ENDOCYTIC AGENTS | BioVentures, LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025128165-A2 | ELECTROPHILIC REACTIVE LINKERS FOR LABELING OF POLYPEPTIDES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143669-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA-FARBER CANCER INSTITUTE, INC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | BRD4 537/4885BRDT 226/4885BRD2 2140/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | BRD4 3192/4885BRDT 1771/4885BRD2 4023/4885 |
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | BRD4 3041/4885BRDT 626/4885BRD2 2990/4885 |
| US-12540143-B2 | Methods and compositions for targeted protein degradation | ADRM1, NCOR1, KDELR1 | BRD4 1065/4885BRDT 1667/4885BRD2 1787/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | BRD4 891/4885BRDT 3079/4885BRD2 1481/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | BRD4 237/4885BRDT 1422/4885BRD2 411/4885 |
| US-20250327028-A1 | ENGINEERED PLATELETS AS TARGETED PROTEIN DEGRADERS | HSP90B1, HSP90AB1, HSP90AA1 | BRD4 3402/4885BRDT 2394/4885BRD2 3340/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | BRD4 4/4885BRDT 8/4885BRD2 9/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | BRD4 3/4885BRDT 16/4885BRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.